News
Paradigm Health and AACI to Present Webinar on 'Pioneering a Modern Regulatory Framework'
Pictured, clockwise from top left: Dr. Ivy Altomare and Kent Thoelke of Paradigm Health; Jeremy Walsh, formerly of U.S. FDA; and Dr. Emma Meagher of Perelman School of Medicine, University of Pennsylvania
Paradigm Health and AACI will present a webinar titled “Pioneering a Modern Regulatory Framework: a Discussion With the Leaders Behind FDA’s Real-Time Clinical Trials” at 11:00 am eastern time on Monday, September 28.
In April 2026, the U.S. Food and Drug Administration (FDA) announced Real-Time Clinical Trials, a landmark initiative to automate data collection and analysis and streamline safety and efficacy reporting to trial sponsors and the FDA in near-real time.
The Paradigm-AACI webinar will bring together the pioneers at the center of the FDA’s proof-of-concept trials to discuss how the collaboration formed, what the initiative means for researchers and clinical development, and why health systems and patients stand to benefit most.
Paradigm Health Vice President of Clinical Research Ivy Altomare, MD, will moderate a panel discussion with Jeremy Walsh, former chief AI officer, U.S. FDA; Emma Meagher, MD, professor of medicine and pharmacology and senior vice dean of clinical and translational research at Perelman School of Medicine, University of Pennsylvania; and Kent Thoelke, founder and chief executive officer, Paradigm Health.
About Paradigm Health
Paradigm Health has developed an AI-powered platform to accelerate and streamline operations and expand patient access to clinical trials at health systems. The platform enables sites to increase the pace of patient identification and recruitment, optimize trial portfolios, and reduce the burden of study data collection.
Paradigm Health’s network consists of community health systems, oncology practice networks, and academic medical centers across the United States, and internationally.
Through the Real-Time Clinical Trials Initiative, a new collaboration with the FDA, The University of Texas MD Anderson Cancer Center, the Perelman School of Medicine at the University of Pennsylvania, Amgen, and AstraZeneca are all using Paradigm Health's platform to dramatically accelerate trial review.Paradigm Health is an AACI Tech Gold. AACI Tech Gold membership connects technology companies with AACI cancer center leaders to exchange ideas, build relationships, and imagine new possibilities for enhancing oncology through technology. In addition to complimentary meeting registrations, exhibit booths, and other benefits, AACI provides infrastructure and support for Tech Gold members to host one webinar or approved initiative for AACI’s full membership each year.